^
    3d
    Safety,efficacy and mechanisms of envolimab and S-1 systemic therapy combined with intraperitoneal endostar in the treatment of gastric/gastric-oesophageal junction adenocarcinoma with malignant ascites in elderly patients over 70 years. (ChiCTR2500115706)
    P=N/A, N=30, Recruiting, Beijing Hospital; Beijing Hospital
    New trial
    |
    Teysuno (gimeracil/oteracil/tegafur) • Endostar (recombinant human endostatin)
    3d
    Sintilimab Plus Systemic Chemotherapy With or Without Intraperitoneal Nab-Paclitaxel for Treatment-Naïve HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Phase III Randomized Controlled Trial (ChiCTR2600117422)
    P3, N=344, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-Sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    3d
    Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study (ChiCTR2500115516)
    P2, N=39, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    oxaliplatin • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    3d
    A prospective, single-center, exploratory phase II clinical study of QL1706 combined with chemotherapy in the treatment of previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer. (ChiCTR2600116087)
    P2, N=32, Not yet recruiting, Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University
    New P2 trial
    |
    HER-2 overexpression • HER-2 amplification
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Qibeian (iparomlimab/tuvonralimab)
    3d
    Liposomal Irinotecan Plus 5-FU/LV Compared with Sequential Alternating nab-Paclitaxel Plus S-1 as Second-Line Therapy in Patients with Advanced Biliary Tract Cancer: A Randomized, Open-Label, Prospective Trial (ChiCTR2500111686)
    P2, N=58, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial
    |
    5-fluorouracil • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    3d
    Prospective Study With HIPEC and AS regimen plus PD-L1 antibody with Fruquintinib in Patients With Peritoneal Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (ChiCTR2500113398)
    P2, N=52, Not yet recruiting, Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    albumin-bound paclitaxel • Fruzaqla (fruquintinib) • Teysuno (gimeracil/oteracil/tegafur)
    5d
    Intraperitoneal Paclitaxel-Induced Eosinophil Recruitment as a Potential Mediator of Tumor Response in Peritoneal Metastases from Gastric Cancer. (PubMed, Ann Surg Oncol)
    IP PTX promotes the recruitment and activation of eosinophils with potent antitumor activity in the peritoneal cavity. Early post-treatment abdominal eosinophilia is a robust prognostic biomarker and may represent a promising therapeutic target to enhance the efficacy of IP chemotherapy in patients with PM from GC.
    Journal
    |
    CD4 (CD4 Molecule) • ITGAM (Integrin, alpha M) • CCR3 (C-C Motif Chemokine Receptor 3) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    6d
    Huaxi: Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=154, Not yet recruiting, Sichuan University
    New P2 trial
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Yidafan (ivonescimab)
    6d
    MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Ruijin Hospital | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    7d
    Two cases of metastatic colorectal cancer in which epidermal growth factor receptor gene amplification benefited from panitumumab monotherapy. (PubMed, Int Cancer Conf J)
    After receiving capecitabine monotherapy as first-line therapy, S-1 plus irinotecan plus bevacizumab therapy as second-line, trifluridine/tipiracil (FTD/TPI) monotherapy as third-line, and regorafenib monotherapy as fourth-line therapy, the patient received panitumumab monotherapy as fifth-line therapy...After receiving mFOLFOX6 plus panitumumab therapy as first-line therapy, FOLFIRI plus bevacizumab as second-line, he underwent conversion surgery...As third-line therapy, he received pembrolizumab monotherapy...We encountered two patients with mCRC and EGFR gene amplification who responded to panitumumab monotherapy. EGFR gene amplification may be a potential biomarker for anti-EGFR antibodies, regardless of RAS status.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden)
    |
    TMB-H • EGFR amplification • RAS mutation • RAS wild-type
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)
    8d
    Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=198, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Trial completion date: Jul 2028 --> Jul 2027 | Trial primary completion date: Feb 2026 --> Dec 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • omeprazole
    8d
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer (clinicaltrials.gov)
    P3, N=387, Recruiting, Ruijin Hospital
    New P3 trial • Head-to-Head
    |
    docetaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)